应用蛋白A免疫吸附技术清除造血干细胞移植后新生供体特异性抗体促进血小板植入的再生障碍性贫血1例  

Eliminating de novo donor specific antibodies with immunoadsorption for improving platelet engraftment after allogeneic hematopoietic stem cell transplantation:one case report

作　　者：李玲[1] 李静[1] 朱倩 周士源[1] 马超 李诗佳 马骁[1] 何军[1] 吴德沛[1] 吴小津[1] Li Ling;Li Jing;Zhu Qian;Zhou Shiyuan;Ma Chao;Li Shijia;Ma Xiao;He Jun;Wu Depei;Wu Xiaojin(Department of Hematology,First Affiliated Hospital,Soochow University,Jiangsu Institute of Hematology,National Clinical Research Center for Blood Diseases,Institute of Hematopoietic Stem Cell Transplantation,Soochow University,Suzhou 215006,China;Department of Hematology,Soochow Hopes Hematology Hospital,Suzhou 215100,China)

机构地区：[1]苏州大学附属第一医院血液内科,国家血液系统疾病临床医学研究中心,江苏省血液研究所,苏州大学造血干细胞移植研究所,苏州215006 [2]苏州弘慈血液病医院,苏州215100

出　　处：《中华器官移植杂志》2024年第3期184-187,共4页Chinese Journal of Organ Transplantation

基　　金：江苏省自然科学基金(BK20211070);江苏省重点研发计划(BE2019798);江苏省医学杰出人才项目(JCRCA2016002);苏州市科技计划项目(SLT201911);苏州市临床重点病种诊疗技术专项项目(LCZX202101)。

摘　　要：通过回顾2021年3月苏州大学附属第一医院收治的1例重型再生障碍性贫血患者,应用蛋白A免疫吸附(immunoadsorption,IA)技术清除造血干细胞移植后新生供体特异性抗体(donor specific antibody,DSA)促进血小板植入的诊疗过程,探讨IA技术清除单倍体造血干细胞移植后新生DSA的疗效和安全性。To explore the efficacy and safety of immunoadsorption(IA)in removing de novo donor specific antibody(DSA)after allogeneic hematopoietic stem cell transplantation(HSCT),the relevant clinical data were retrospectively reviewed for one female patient of severe aplastic anemia(SAA).Desensitization treatment with IA after HSCT was offered for removing de novo DSA and ultimately promoting platelet engraftment at First Affiliated Hospital of Soochow University in March 2021.

关 键 词：再生障碍性贫血 免疫吸附 单倍体造血干细胞移植 供者特异性抗体 

分 类 号：R457.7[医药卫生—治疗学]